NeurAxis, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a medical technology company built around PENFS neuromodulation. Its 8-K reports cover preliminary operating results, FDA 510(k) clearance for PENFS indications, at-the-market common stock offering arrangements under a Form S-3 registration statement, related prospectus supplements and legal opinions, and material agreements involving licensed neuromodulation assets.
NeurAxis proxy materials disclose annual meeting matters, director elections, auditor ratification, equity incentive plan amendments, an employee stock purchase plan, and voting rights involving common stock and Series B Preferred Stock. The filing record also documents corporate governance, stock-based compensation plans, material contract changes, and risk-bearing financing mechanisms tied to its commercialization strategy.
Neuraxis, Inc. (NRXS) Form 4 filing shows Director and 10% owner Brian P. Hannasch purchased 355,556 common shares on 07/01/2025 at $2.25 per share, an estimated cash outlay of roughly $0.8 million. The transaction was coded “P” (open-market purchase), executed directly, and lifts Hannasch’s total direct holdings to 1,131,522 shares.
Key take-aways:
- The purchase represents a sizable vote of confidence by a control insider.
- Post-transaction ownership exceeds one million shares, reinforcing alignment with minority shareholders.
- No disposals or derivative transactions were reported.
The filing contains no additional financial data or explanatory notes beyond the standard certification.